Codelac neo pi n / a film about modif.vysvobozhdeniem 10 pcs 50mg

Description

Composition
Active substance:
1 tablet contains: butamirata citrate – 50.00 mg ;.
Excipients:
Lactose monohydrate (milk sugar) – 241.00 mg Hypromellose (Methocel K4M-) – 85.00 mg talc – 4.00 mg magnesium stearate – 4.00 mg colloidal silica (Aerosil) – 6.00 mg , a low molecular weight povidone (polyvinylpyrrolidone, low molecular weight) – 5.00 mg;
Coating: Opadry white (Opadry II White 57M280000) (in the form of a powder containing hypromellose (15 cps) – 5.58 mg titanium dioxide – 4.86 mg, polydextrose – 4.68 mg talc – 1.26 mg, Maltodextrin / dextrin – 0.90 mg glycerin / glycerol – 0.72 mg) – 18.00 mg.
Description:
Round biconvex tablets, film-coated white. The cross sectional tablets white or nearly white.
Product form:
The modified-release tablet, film-coated, 50 mg. 10 tablets in blisters of PVC film and printing blank lacquered aluminum. At 30 or 50 tablets in a jar polymer. 1, 2, blisters or jar along with instructions for medical application is placed in a pile of cardboard.
Contraindications
Increased sensitivity to the drug, pregnancy (I term), lactation, lactose intolerance, lactase deficiency, glucose-galactose malabsorption. Children up to age 18 years.
Carefully
Pregnancy (II and III trimester).
Dosage
50 mg
Indications
Dry cough from any cause (for “common cold” diseases, influenza, whooping cough and other conditions). Cough suppressants in the preoperative and postoperative surgical interventions and bronchoscopy.
Interaction with other drugs
Any drug interactions are not described for butamirata. In the period of treatment is not recommended to drink alcohol, and drugs that suppress the central nervous system (hypnotics, neuroleptics, tranquilizers and other drugs).
Due to the fact that butamirata suppresses the cough reflex, avoid simultaneous use of expectorants to avoid accumulation of mucus in the airways of the risk of bronchospasm and respiratory tract infections.
Overdose
Symptoms include nausea, vomiting, drowsiness, diarrhea, abdominal pain, dizziness, irritability, decreased blood pressure, impaired motor coordination.
Treatment: gastric lavage, activated charcoal, saline laxatives, symptomatic therapy (if indicated).
pharmachologic effect
Pharmacological group:
Antitussive central action.
Pharmacodynamics:
Butamirata, active agent formulation Codelac® Neo, is a centrally acting antitussive. Does not apply to opium alkaloids do not chemically or pharmacologically. It does not produce dependence or addiction.
Suppresses cough, having a direct effect on the cough center. It has bronchodilatory effect (expands bronchi). It helps to alleviate respiratory spirometry improves (reduces airway resistance) and blood oxygenation (saturates the blood with oxygen).
Pharmacokinetics:
Absorption – high. After oral tablets with modified release maximum plasma concentration of the main metabolite (2-phenylbutyric acid) was observed after 9 hours and 1.4 ug / ml.
Hydrolysis butamirata initially to 2-phenylbutyric acid and dietilaminoetoksietanola starts in blood. These metabolites also possess antitussive activity, and, like butamirata largely (about 95%) bind to plasma proteins, which leads to their long half-life. 2-phenylbutyric acid is partially metabolized by hydroxylation. Repeated dose drug accumulation was observed.
The half-life butamirata -. 13 hours Metabolites derived mainly kidneys. Moreover, 2-phenylbutyric acid mostly appears in the associated form of glucuronic acid.
Pregnancy and breast-feeding
No safety data, use during pregnancy, and it passes through the placental barrier. Use of the drug in the first trimester of pregnancy is contraindicated. In II and III trimester of pregnancy, the use of the drug is possible, taking into account the ratio of benefits to the mother and the potential risk to the fetus. The penetration of the drug into breast milk has not been studied, so the use of the drug during breast feeding is not recommended.
Conditions of supply of pharmacies
Without recipe.
side effects
Classification of the incidence of adverse reactions: very common (> 1/10), common (> 1/100,
special instructions
Each tablet contains 241 mg of lactose. The drug is contraindicated in patients with lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
It is recommended to refrain from driving and other activities potentially hazardous activities that require high concentration and speed of psychomotor reactions, because the drug can cause drowsiness and dizziness.
Storage conditions
Store at a temperature not higher than 25 C. Keep out of reach of children !.
Dosing and Administration
Inside.
Tablets are taken before a meal, without chewing. 1 tablet every 8-12 hours.
If cough persists for more than 5 days after the start of treatment, you should consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist